Jeffrey Johnson, MD
Cardiovascular Disease · Knoxville, TNNPI 1285635961
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Daxor Corporation at 55.3% of the total. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $237.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daxor Corporation$52K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
- Esperion Therapeutics, Inc.$10K
- Novartis$7K
- Johnson & Johnson$557
- Amgen$505
- plus $2K from 29 others
What the payments were for
- Consulting fees$42,00045%
- Speaking & faculty fees$43,90047%
- Travel & lodging$410%
- Food & beverage$8,3319%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daxor Corporation | 52 | $52,147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 101 | $21,561 |
| Esperion Therapeutics, Inc. | 15 | $9,581 |
| Novartis | 39 | $7,466 |
| Johnson & Johnson | 41 | $557 |
| Amgen | 28 | $505 |
| Pfizer | 23 | $346 |
| Abbott | 13 | $269 |
| Boehringer Ingelheim | 10 | $241 |
| Boston Scientific | 12 | $236 |
| AstraZeneca | 4 | $163 |
| Atricure, Inc. | 3 | $148 |
| Actelion Pharmaceuticals US, Inc. | 9 | $129 |
| Sanofi-aventis U.S. LLC | 8 | $120 |
| Inspire Medical Systems, Inc. | 3 | $115 |
| E.r. Squibb & Sons, L.L.C. | 7 | $112 |
| Heartflow, Inc. | 1 | $68 |
| Abiomed | 1 | $56 |
| Amarin Pharma, Inc. | 3 | $52 |
| Gilead | 4 | $52 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Akcea Therapeutics, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Irhythm Technologies, Inc. | 2 | $25 |
| Teleflex LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Vital Connect, Inc | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $17 |
| Sanofi | 1 | $16 |
| Bayer | 1 | $15 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,290 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 481 | $447,097 |
| XareltoRivaroxaban | 116 | $136,065 |
| EntrestoSacubitril/Valsartan | 109 | $104,934 |
| BrilintaTicagrelor | 62 | $35,194 |
| JardianceEmpagliflozin | 19 | $26,494 |
| Repatha SureclickEvolocumab | 32 | $24,705 |
| MultaqDronedarone Hcl | 15 | $20,574 |
| Ranolazine ErRanolazine | 73 | $10,624 |
| Metoprolol Succinate | 499 | $6,063 |
| Nebivolol Hcl | 62 | $5,348 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $4,323 |
| Prasugrel Hcl | 34 | $4,204 |
| Rosuvastatin Calcium | 243 | $3,427 |
| Flecainide Acetate | 86 | $3,049 |
| Atorvastatin Calcium | 224 | $2,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $447,097481 claims |
| Johnson & JohnsonXarelto | $557 | $136,065116 claims |
| NovartisEntresto | $7,466 | $104,934109 claims |
| AstraZenecaBrilinta | $163 | $35,19462 claims |
| Boehringer IngelheimJardiance | $241 | $26,49419 claims |
| Sanofi-aventis U.S. LLCMultaq | $120 | $20,57415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Knoxville
- Neil BarryKnoxville$23K
- Joseph LiuKnoxville$22K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
- George CrossleyNashville$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.